Welireg (belzutifan) — Highmark
advanced renal cell carcinoma (RCC) with a clear cell component
Initial criteria
- age ≥ 18 years
- diagnosis of advanced renal cell carcinoma (RCC) with a clear cell component
- received prior treatment with a PD-1 inhibitor (e.g., pembrolizumab, nivolumab) OR a PD-L1 inhibitor (e.g., avelumab)
- received prior treatment with a VEGF-TKI (e.g., axitinib, cabozantinib, lenvatinib)
Reauthorization criteria
- prescriber attests that the member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months